Vimarsana
Biggest News Aggregation in the World

Mark Rutstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Rutstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Rutstein Today - Breaking & Trending Today

Harpoon Therapeutics : April 3, 2024 -April 03, 2024 at 08:32 am EDT - Vimarsana News

Harpoon Therapeutics : April 3, 2024 -April 03, 2024 at 08:32 am EDT

Published: April 3, 2024

BASKING RIDGE, N.J. & RAHWAY, N.J., April 3, 2024 - Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been...

Source: marketscreener.com
Related Topics:
Sri LankaUnited StatesKoji OgiwaraCarly MyarPeter DannenbaumMark RutsteinJennifer BrennanDamini ChokshiDaiichi SankyoRobert JosephsonMerck Co IncMerck Research LaboratoriesDevelopment Innovations In NashvilleStatement Of Merck Co IncExchange CommissionEuropean Society For Medical Oncology CongressSociety For Gynecologic OncologySarah Cannon Research InstituteEuropean SocietyMedical Oncology CongressGynecologic OncologyMarjorie GreenMerck ResearchNorth AmericaLooking Statement
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer - Vimarsana News

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Published: April 3, 2024

Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the...

Source: marketscreener.com
Related Topics:
Sri LankaUnited StatesDaiichi SankyoRaludotatug DeruxtecanMark RutsteinEuropean Society For Medical Oncology CongressMerck Research LaboratoriesSarah Cannon Research InstituteExchange CommissionSociety For Gynecologic OncologyStatement Of Merck Co IncOncology Clinical DevelopmentGlobal Clinical DevelopmentDevelopment Innovations In NashvilleMerck Co IncEuropean SocietyMedical Oncology CongressGynecologic OncologyGlobal HeadMarjorie GreenSenior Vice PresidentLate Stage OncologyMerck ResearchNorth AmericaMerck Collaboration
Daiichi Sankyo : Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes(241.9KB -December 18, 2023 at 08:07 am EST - Vimarsana News

Daiichi Sankyo : Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes(241.9KB -December 18, 2023 at 08:07 am EST

Published: December 18, 2023

Press Release Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes ...

Source: marketscreener.com
Related Topics:
United StatesKoji OgiwaraJennifer BrennanCristian MassacesiDaiichi SankyoMark RutsteinOncology Clinical DevelopmentSapporo Medical UniversityAmerican Cancer Society TreatmentDaiichi Sankyo Co LtdNational Cancer InstituteDaiichi Sankyo IncMerck Co IncPress ReleaseDatopotamab Deruxtecan Plus Durvalumab InitiatedPatients Across Two Breast Cancer SubtypesBasking RidgeGlobal HeadChief Medical OfficerOncology Chief Development OfficerNorth AmericaHormone Receptor LowNegative Breast CancerAstrazeneca CollaborationDatopotamab Deruxtecan
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial - Vimarsana News

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Published: October 23, 2023

Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population Results reaffirm...

Source: marketscreener.com
Related Topics:
United StatesDaiichi SankyoCristian MassacesiMark RutsteinMerck Co IncNational Cancer InstituteAmerican Society Of Clinical OncologyOncology Clinical DevelopmentEuropean Society For Medical OncologyUniversity Of Texas Md Anderson Cancer CenterClinical Development ProgramDaiichi Sankyo IncEuropean SocietyMedical OncologyClinical OncologyFunda Meric BernstamInvestigational Cancer TherapeuticsCancer CenterPrincipal InvestigatorGlobal HeadChief Medical OfficerOncology Chief Development OfficerInvestigator AssessedLung DiseaseBreast Cancer
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial - Vimarsana News

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Published: October 22, 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--

Source: joplinglobe.com
Related Topics:
City OfUnited KingdomUnited StatesJennifer BrennanDaiichi SankyoCristian MassacesiKoji OgiwaraMark RutsteinPeter SchmidSapporo Medical UniversityBarts Cancer InstituteDaiichi Sankyo IncEuropean Society For Medical OncologyMerck Co IncNational Cancer InstituteDaiichi Sankyo Co LtdOncology Clinical DevelopmentEuropean SocietyMedical OncologyGlobal HeadChief Medical OfficerOncology Chief Development OfficerDatopotamab DeruxtecanNatl CancerCancer Institute